Literature DB >> 33040746

Benzodiazepines: it's time to return to the evidence.

Edward Silberman1, Richard Balon2, Vladan Starcevic3, Richard Shader4, Fiammetta Cosci5, Giovanni A Fava6, Antonio E Nardi7, Carl Salzman8, Nicoletta Sonino9.   

Abstract

SUMMARY: We propose that discussions of benzodiazepines in the current psychiatric literature have become negatively biased and have strayed from the scientific evidence base. We advocate returning to the evidence in discussing benzodiazepines and adhering to clear definitions and conceptual rigour in commentary about them.

Entities:  

Keywords:  Anti-anxiety drugs; anxiety disorders; comorbidity; drug interactions and side-effects; drugs of dependence

Mesh:

Substances:

Year:  2021        PMID: 33040746     DOI: 10.1192/bjp.2020.164

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN: 0007-1250            Impact factor:   9.319


  3 in total

1.  Anxiety in the Medically Ill: A Systematic Review of the Literature.

Authors:  Sara Romanazzo; Giovanni Mansueto; Fiammetta Cosci
Journal:  Front Psychiatry       Date:  2022-06-03       Impact factor: 5.435

2.  An examination of the medicalization and pharmaceuticalization processes of anxiety and depressive disorders in Belgium between 2004 and 2013: how may both disorders be intertwined?

Authors:  Van Looy Kilian; Van de Velde Sarah
Journal:  Arch Public Health       Date:  2022-08-15

Review 3.  Benzodiazepine high-doses: The need for an accurate definition.

Authors:  Jean-Marc Cloos; Christopher Y S Lim Cow; Valéry Bocquet
Journal:  Int J Methods Psychiatr Res       Date:  2021-07-31       Impact factor: 4.035

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.